Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Flyer

Journal of Biomedical Sciences

  • ISSN: 2254-609X
  • Journal h-index: 18
  • Journal CiteScore: 4.95
  • Journal Impact Factor: 4.78
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Google Scholar citation report
Citations : 1283

Journal of Biomedical Sciences received 1283 citations as per Google Scholar report

Flyer image
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
View More
Share This Page

Kantharaj Ethirajulu

Kantharaj Ethirajulu
Head of Research and Development technical, D3 Biomedical Science Institute (BMSI), Singapore

Biography

Professional drug discovery & development leader with 22 years of experience in DMPK and Early development across therapy areas in both small biotech and large pharmaceutical setting. Skilled manager possessing the ability to function effectively in matrix environments. Successfully built and led cohesive teams, managed and trained staff across multiple levels. I have provided scientific leadership in DMPK/tox, to drive projects from Hit-generation, lead optimization and selection of preclinical development candidates. Championed and developed new scientific ideas and concepts specifically focused on DMPK related design activities. Amongst the first towards the development and scientific validation of in vitro DMPK assays in high-throughput fashion in the Industry while working at AstraZeneca and Johnson and Johnson. Represented the DMPK/tox function in early project teams and provided expert opinion on the design of new molecules, building DMPK SAR relationship, providing guidance to medicinal chemistry on DMPK/tox related matter. Prepared and represented project matters at the stage-gate review project meetings to facilitate informed decision-making. Provided the DMPK/tox section of documents used for internal decision-making and regulatory path direction. Have monitored for studies outsourced to CROs as sponsor-study director. Analyse and provide overview of the competitive landscape and the DMPK/tox properties of our competitors? molecules, back translate available PK as well as PK/PD data and provides solutions for potential differentiation. Input and drive scientific innovation in projects leading to best-in-class molecules. Contributed actively to the design of pharmacological studies. Provided scientific support towards the design of new molecules by correlating existing DMPK, potency and phys-chem data to structural motives. I am an outstanding negotiator, influencer, and problem-solver with a firm stand on deliverables and agreed-on goals. KEY ACCOMPLISHMENTS

Research Interest

drug discovery